Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Thyroid Nodule 1Thyroid Neoplasms 1Thyroid Diseases 1Solitary Fibrous Tumors 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Pruritus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Parathyroid Neoplasms 1Parathyroid Diseases 1Ovarian Neoplasms 1Opioid-Related Disorders 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Capsules × Clear all
NCT04094610 2025-11-19

A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
75 enrolled
CNSLymphoidPlasma cellSarcoma

Glioblastoma, Glioma, Granuloma, Plasma Cell, Lymphoma, Neoplasm Metastasis, Sarcoma, Lymphoma, Large-Cell, Anaplastic, Solitary Fibrous Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡